Men’s health-focused startup Posterity has raised $13 million in a Series A funding round, signaling growing investor interest in male fertility solutions amid increasing concerns over declining sperm counts.
Breaking the Stigma in Male Fertility
Despite rising awareness, fertility treatment remains largely framed as a women’s health issue, often placing the burden of seeking care on women. Posterity aims to shift this narrative by making male fertility services more accessible and reducing the stigma surrounding them.
Investment and Growth Plans
The funding round was led by Georgetown Equity Partners, with participation from FCA Venture Partners, Distributed Ventures, WVV, and new investors SteelSky Ventures and Scrub Capital. The capital will be used to refine Posterity’s technology, expand into areas like weight loss, and scale marketing efforts.
Although the Colorado-based company has yet to turn a profit, it has seen steady growth. Last year, Posterity treated 12,000 patients, with 60% of referrals coming from fertility centers and urologists, while the remaining 40% were through insurers.
Comprehensive Male Fertility Services
Posterity offers a blend of digital and in-person services, including fertility testing, hormone therapy, vasectomies, and vasectomy reversals. The company is working to break the cycle of care avoidance in men, promoting education and proactive health management.
“A big part of our mission is education—helping men take ownership of their health and approach fertility as a shared journey with their partners,” said CEO Pure.
Expanding the Market for Male Fertility
SteelSky Ventures partner Maria Toler noted that Posterity is tapping into a generational shift, where more men want to be involved in fertility planning rather than leaving the responsibility solely to women.
The Competitive Landscape
The male fertility space is gaining traction, with companies like Legacy, Yo, Mojo, Path, and Fellow also securing funding. Recent deals include:
- Legacy raising $25 million in Series B funding at a $150 million valuation.
- Next Life Sciences securing $2.5 million for male contraceptive development.
- Ro acquiring sperm storage startup Dadi for $100 million in 2022.
Looking Ahead
With growing awareness and investment in male reproductive health, Posterity’s latest funding round underscores the shifting landscape of fertility care—one that increasingly recognizes men as active participants in family planning.
Related topics:
Understanding the Impact of Diseases on Sexual and Reproductive Health: Expert Insights
Creating a Compassionate Workplace: Supporting Employees Through Infertility and Pregnancy Loss
